KDM1 class flavin-dependent protein lysine demethylases

Biopolymers
Jonathan M BurgDewey G McCafferty

Abstract

Flavin-dependent, lysine-specific protein demethylases (KDM1s) are a subfamily of amine oxidases that catalyze the selective posttranslational oxidative demethylation of methyllysine side chains within protein and peptide substrates. KDM1s participate in the widespread epigenetic regulation of both normal and disease state transcriptional programs. Their activities are central to various cellular functions, such as hematopoietic and neuronal differentiation, cancer proliferation and metastasis, and viral lytic replication and establishment of latency. Interestingly, KDM1s function as catalytic subunits within complexes with coregulatory molecules that modulate enzymatic activity of the demethylases and coordinate their access to specific substrates at distinct sites within the cell and chromatin. Although several classes of KDM1-selective small molecule inhibitors have been recently developed, these pan-active site inhibition strategies lack the ability to selectively discriminate between KDM1 activity in specific, and occasionally opposing, functional contexts within these complexes. Here we review the discovery of this class of demethylases, their structures, chemical mechanisms, and specificity. Additionally, we review inhib...Continue Reading

References

Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·K IwabuchiS Fields
Sep 25, 1998·The Journal of Biological Chemistry·K IwabuchiS Fields
Aug 18, 1999·Proceedings of the National Academy of Sciences of the United States of America·M E AndrésG Mandel
Nov 2, 1999·The EMBO Journal·R E KiernanC Van Lint
Mar 1, 2000·Trends in Biochemical Sciences·M W Fraaije, A Mattevi
Mar 29, 2000·The Journal of Biological Chemistry·J A GrimesT Kouzarides
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A YouS L Schreiber
Jun 16, 2001·Bioorganic & Medicinal Chemistry·H ImamuraH Morishima
Apr 5, 2002·Molecular Cell·Shiraz MujtabaMing-Ming Zhou
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mohamed-Ali HakimiRamin Shiekhattar
Oct 26, 2002·Science·Victoria V LunyakMichael G Rosenfeld
Dec 21, 2002·The Journal of Biological Chemistry·Mohamed-Ali HakimiRamin Shiekhattar
Feb 4, 2003·Experimental Biology and Medicine·William B Pratt, David O Toft
Jun 27, 2003·Trends in Biochemical Sciences·Joanna Wysocka, Winship Herr
Jul 31, 2003·Molecular Cell·Katrin KaehlckeMelanie Ott
Aug 30, 2003·EMBO Reports·Cécile CaronSaadi Khochbin
May 1, 1964·Proceedings of the National Academy of Sciences of the United States of America·V G ALLFREYA E MIRSKY
Oct 3, 2003·Journal of Medicinal Chemistry·James SeidlerBrian K Shoichet
Nov 1, 2003·Science·Yuehui HeRichard M Amasino
Dec 18, 2003·Drug Discovery Today·Hartmuth C Kolb, K Barry Sharpless
Apr 3, 2004·Nucleic Acids Research·Audrey CastetVincent Cavaillès
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jun 15, 2004·Cancer Cell·Jennifer O'NeilMichelle Kelliher
Aug 25, 2004·Biochemical and Biophysical Research Communications·Shigeki IwaseTadashi Baba
Dec 29, 2004·Cell·Stefan Kubicek, Thomas Jenuwein
Apr 7, 2005·FEBS Letters·Federico FornerisElena Battaglioli

❮ Previous
Next ❯

Citations

Feb 18, 2016·Medical Hypotheses·Benjamin A GarciaConrad Wagner
Feb 19, 2016·ChemMedChem·A Ganesan
Apr 15, 2016·Expert Opinion on Investigational Drugs·Amanda Przespolewski, Eunice S Wang
Oct 19, 2016·Clinical Epigenetics·Angel R de Lera, A Ganesan
Sep 29, 2020·Briefings in Bioinformatics·Zerong WangYongchun Zuo
Mar 10, 2017·Epigenetics : Official Journal of the DNA Methylation Society·Hideaki Niwa, Takashi Umehara
May 4, 2017·Cell Cycle·Matthieu SchoenhalsJérôme Moreaux
Jun 21, 2018·Epigenetics & Chromatin·Tayaba IsmailHyun-Shik Lee
May 24, 2020·Scientific Reports·Junya TamaokiMakoto Kobayashi
Sep 17, 2016·The Journal of Biological Chemistry·Emily L RicqStephen J Haggarty
Jun 20, 2019·Frontiers in Plant Science·Damiano MartignagoParaskevi Tavladoraki
Oct 28, 2019·Frontiers in Oncology·Maaike G J M van Bergen, Bert A van der Reijden
Apr 25, 2018·Bioorganic & Medicinal Chemistry Letters·Anup K UpadhyayChaohong Sun
Mar 4, 2021·Life·Abdurrahman Pharmacy YusufGaber El-Saber Batiha
Feb 13, 2019·Bioorganic & Medicinal Chemistry·Yuka MiyakeTakayoshi Suzuki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.